Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis.
The mechanism of action of recombinant IFNbeta1b (IFNbeta-1b), as a therapy for multiple sclerosis (MS), is still unknown but may result from the enhancement of ConA-induced suppressor cell function and the inhibition of IFNgamma secretion by lymphocytes. We previously demonstrated that IFNbeta-1b stimulated modest amounts of IL-10 secretion by monocytes and IL-10 activity, as cytokine synthesis inhibitory factor, was normal in MS. To determine whether IL-10 plays a role in IFNbeta-1b modulation of immune function in MS, we studied ConA-induced suppressor cell function and IFNgamma production in presence of IFNbeta-1b and an anti-IL-10 monoclonal antibody (mAb). Anti-IL-10 mAb significantly reduced the effect of IFNbeta-1b on ConA-induced suppressor cell function and IFNgamma production in healthy subjects; MS patients showed a trend of inhibition. We hypothesized that IL-10 may play a role in mediating the effects of IFNbeta-1b on suppressor cell function and IFNgamma production but suppressor molecules other than IL-10 could be also involved.
Porrini
A M
AM
Institute of Clinical Neurology and Behavioral Sciences, University of Chieti, Italy.
De Luca
G
G
Gambi
D
D
Reder
A T
AT
D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000276:immunology* / Q000628:therapy; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000494:pharmacology*; D016753:Interleukin-10 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism / Q000502:physiology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D011993:Recombinant Fusion Proteins; D003208:Concanavalin A; D016753:Interleukin-10; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a